Zynex

Zynex ROE

Delisted

The Return on Equity (ROE) of Zynex (ZYXI) as of Nov 22, 2026 is 8.38 %. In the previous year, Return on Equity (ROE) was 21.10 % — a change of -60.26% (lower).

ROE

8.38 %

YoY

-60.26%

Last updated:

In 2024, Zynex's return on equity (ROE) was 8.38 %, a -60.26% increase from the 21.10 % ROE in the previous year.

The Zynex ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2017
147.57 USD
Jan 1, 2018
101.76 USD
Jan 1, 2019
48.08 USD
Jan 1, 2020
15.96 USD
Jan 1, 2021
23.14 USD
Jan 1, 2022
25.69 USD
Jan 1, 2023
21.10 USD
Jan 1, 2024
8.38 USD
The Zynex ROE history
YEARROEYoY
8.38 %-60.26%
21.10 %-17.88%
25.69 %+11.05%
23.14 %+44.96%
15.96 %-66.81%
48.08 %-52.75%
101.76 %-31.04%
147.57 %-8,040.74%
-1.86 %-102.54%
73.10 %-85.84%
516.15 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zynex Stock analysis

What does Zynex do? Zynex Inc is an American company that manufactures and distributes medical devices and accessories. The company was founded in 1996 and is headquartered in Englewood, Colorado. In recent years, it has become a major player in the pain therapy market. The history of Zynex began with the development of a neurotherapeutic system called NeuroMove, which aimed to restore mobility in patients with paralysis after strokes or other neurological disorders. The company uses proprietary technology to provide safe and effective electrotherapeutic stimulation, which helps trigger muscle contractions and improve mobility. Over the years, the company has specialized in the development and sale of medical devices for pain therapy and rehabilitation. Zynex's products can be used in various areas, including electrostimulation, TENS and EMS therapy, home diagnostics, as well as blood pressure and oxygen measurement. Zynex offers devices specifically for pain therapy. These devices are used by many doctors and physiotherapists to support patients in their healing process. The company's flagship product is the Nexus D-11 EMS and TENS device, which is capable of conducting multiple pain treatments simultaneously. Another important device from Zynex is the InWave system, which applies FDA-approved electromagnetic wave therapy. The therapy is used for both acute and chronic pain and aims to promote the body's natural healing processes to relieve pain. Zynex also manufactures home diagnostic devices such as the blood sugar monitor and pulse oximeter, which can be regularly used by patients at home to monitor their well-being. These products help individuals develop an understanding of how their body responds to different treatments or environmental conditions. An important aspect of Zynex's business model is collaborating with healthcare customers. The company forms partnerships with medical facilities and practitioners to ensure that its products are effectively and safely utilized. These partnerships often include training programs to ensure that users of each device develop a basic understanding of how it works to ensure quality treatment. Zynex has also established a subsidiary called Zynex Medical Europe, which operates in European regions. The company is based in the Netherlands and is responsible for marketing and distributing Zynex's products in Europe. Overall, Zynex has established itself as a key player in the field of pain therapy and rehabilitation. Through its innovative technology and healthcare partnerships, the company is able to provide the best possible patient care. Zynex is one of the most popular companies on Eulerpool.

ROE Details

Decoding Zynex's Return on Equity (ROE)

Zynex's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Zynex's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Zynex's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Zynex’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Zynex stock

Return on Equity (ROE) of Zynex is 8.38 % in 2024.

Return on Equity (ROE) of Zynex changed from 21.10 % to 8.38 %, representing a -60.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Zynex since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Zynex with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Zynex

All Key Metrics — Zynex